Search
Reproxalap
go.drugbank.com/drugs/DB16688Investigational[L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis
Cetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Sitamaquine
go.drugbank.com/drugs/DB04909InvestigationalWR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of
IDM-4
go.drugbank.com/drugs/DB05438ExperimentalIDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … Trials of this drug have most likely been discontinued by the manufacturer.
Surotomycin
go.drugbank.com/drugs/DB12076InvestigationalDifficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. … Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection.
NXN-188
go.drugbank.com/drugs/DB06096InvestigationalNXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
IDD-3
go.drugbank.com/drugs/DB05427ExperimentalIt consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
BBV152
go.drugbank.com/drugs/DB15847Investigationalor a novel TLR7/8 agonist adsorbed gel. … The components of the vaccine include BBV152A, BBV152B, and BBV152C.
REN-850
go.drugbank.com/drugs/DB05912ExperimentalREN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.